Cite this answer
Orforglipron: quick citable summary
Orforglipron is listed by PeptaHub as a weight loss peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Orforglipron: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/orforglipron. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/orforglipron.
What is Orforglipron?
Orforglipron is Foundayo, the FDA-approved oral GLP-1 pill for chronic weight management. It is a small molecule, not a peptide injection and not oral semaglutide. The key tradeoff is pill convenience vs injectable GLP-1 outcome depth.[2]
GLP-1 comparison
Educational only. This comparison is not medical advice, does not recommend any medication, and separates FDA-approved prescription drugs from investigational compounds and fast-changing compounding rules.
| Agent | Brand terms | Mechanism | Regulatory angle | Evidence note |
|---|---|---|---|---|
| Semaglutide | Ozempic / Wegovy / Rybelsus | GLP-1 receptor agonist | FDA-approved prescription drug for type 2 diabetes, chronic weight management, and selected cardiovascular-risk indications by product label. | Deepest outcomes dataset in the cluster: STEP, SUSTAIN, SELECT, FLOW, and PIONEER programs. |
| Tirzepatide | Mounjaro / Zepbound | Dual GIP / GLP-1 receptor agonist | FDA-approved prescription drug for type 2 diabetes, chronic weight management, and obstructive sleep apnea in adults with obesity by product label. | SURPASS and SURMOUNT trials show greater average weight loss than semaglutide in head-to-head and cross-trial contexts. |
| Retatrutide | LY3437943, no approved brand | Triple GIP / GLP-1 / glucagon receptor agonist | Investigational only. Not FDA-approved and not legally available outside clinical trials or regulator-authorized access pathways. | Phase 2 and emerging Phase 3 data are high-interest but still lack approval, label review, and long-term post-market safety data. |
| Orforglipron | Foundayo | Oral small-molecule GLP-1 receptor agonist | FDA-approved prescription drug for chronic weight management in eligible adults; diabetes status requires current-label confirmation. | ATTAIN trials support the oral GLP-1 pill frame: no injection and no food or water restrictions, with less outcomes history than injectable semaglutide. |
Overview
Orforglipron (LY3502970, brand name Foundayo) is Lilly's oral GLP-1 pill: a once-daily, small-molecule, non-peptide GLP-1 receptor agonistreceptor agonist. The answer-first distinction is simple: it is not a peptide structure, not an injection, and not oral semaglutide. It is a small molecule designed for oral absorption without the food, water, and timing restrictions used with Rybelsus (oral semaglutide).
In April 2026, the FDA approved Foundayo (orforglipron) for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related medical problem, alongside diet and physical activity. That makes it a prescription obesity medication, not a research peptide and not a supplement. Diabetes use is a separate regulatory question and should be checked against the current FDA label rather than inferred from obesity approval.
The search demand around orforglipron is unusually young because it sits at the intersection of three phrases people use differently: orforglipron, Foundayo, and the GLP-1 pill. For patients and researchers comparing the class, the practical frame is oral GLP-1 convenience versus injectable GLP-1 efficacy and experience. Compared with Wegovy/Ozempic injections, Foundayo removes needle burden. Compared with Rybelsus, it uses a different small-molecule chemistry rather than a peptide tablet that needs an absorption enhancer.
Mechanism of action
Orforglipron activates the GLP-1 receptor through a non-peptide small-molecule binding mode. GLP-1 receptor activation is associated with glucose-dependent insulin secretion, reduced glucagon signaling, delayed gastric emptying, and central satiety signaling. Those effects overlap with the broader GLP-1 receptor agonistagonist class, but the molecule is chemically distinct from peptide drugs such as semaglutide and liraglutide.
The oral-pill angle is not just packaging. Peptide GLP-1 drugs are usually injected because digestive enzymes and poor intestinal permeability make oral delivery difficult. Oral semaglutide works by pairing the peptide with the SNAC absorption enhancer and strict administration conditions. Orforglipron was developed as a small molecule, so its oral absorption does not depend on peptide-protection technology or injection-device logistics.
This page is educational and does not give dosing instructions. Use the FDA label and a licensed clinician for prescribing, contraindications, dose escalation, missed-dose questions, pregnancy considerations, pancreatitis/gallbladder warnings, and drug-interaction review.
Reported study ranges
No reported study ranges available yet.
Research summary
The pivotal obesity evidence comes from Lilly's ATTAIN Phase 3 program. In ATTAIN-1, a 72-week trial in adults with obesity or overweight without diabetes, participants assigned to the highest studied orforglipron arm lost an average of 27.3 lb, or 12.4% body weight, among those who stayed on treatment, compared with 2.2 lb, or 0.9%, on placebo. Lilly also reported an efficacy-estimand analysis showing 25 lb, or 11.1%, versus 5.3 lb, or 2.1%, for placebo.
ATTAIN-2 studied adults with obesity or overweight and type 2 diabetes. The program supports the obesity approval, while diabetes-specific U.S. approval should not be assumed unless the FDA label lists it. That distinction matters for YMYL accuracy: obesity approval, diabetes trial evidence, and diabetes indication approval are separate claims.
The best comparison is not 'pill equals injection.' Injectable semaglutide and tirzepatide have deeper outcomes datasets, longer post-market experience, and in tirzepatide's case higher average weight-loss efficacy in major trials. Orforglipron's demand is driven by a different value proposition: an FDA-approved oral GLP-1 option for people who want to avoid injections and who need a prescription medication rather than a compounded or research-market product.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Orforglipron for synergistic effects.
Legal status
FDA-approved in April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or overweight with at least one weight-related medical problem, as an adjunct to diet and physical activity. Prescription only. Diabetes use and other indications require current-label confirmation.
Sourcing & access
Prescription required
Orforglipron is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Orforglipron is Lilly's oral small-molecule GLP-1 receptor agonist, approved under the brand name Foundayo for chronic weight management in eligible adults. It is best understood as the GLP-1 pill: no peptide structure and no injection device.
Yes. Foundayo is the approved brand name for orforglipron. People may search for Foundayo, orforglipron, oral GLP-1, or GLP-1 pill when they mean the same prescription medicine.
Yes. The FDA approved Foundayo (orforglipron) in April 2026 for chronic weight management in adults with obesity, or adults with overweight plus a weight-related medical problem. Separate diabetes-indication status should be checked against the current FDA label.
No. Orforglipron is a non-peptide small molecule. That is why it can be framed differently from injectable peptide GLP-1 drugs such as semaglutide and liraglutide.
Oral semaglutide is still a peptide and uses SNAC absorption technology with specific administration conditions. Orforglipron is a small molecule designed for oral absorption without those food and water restrictions.
ATTAIN-1 showed clinically meaningful average weight loss over 72 weeks versus placebo, with Lilly reporting 27.3 lb, or 12.4%, among participants who stayed on the highest studied treatment arm. ATTAIN-2 studied people with type 2 diabetes, but diabetes approval should be treated separately from obesity approval.
No. This is YMYL educational content and does not provide dosing instructions. Use the current prescribing information and a licensed clinician for dose selection, escalation, contraindications, and safety monitoring.
Research references
- FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsFDA
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityPubMed
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyPubMed
- Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: Phase 1b study in people with type 2 diabetesPubMed